- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 30, 2022Anne Lockner Elected Chair of The Fund For Legal Aid
-
June 30, 2022Ashton Batchelor Named Chief Value and Analytics Officer
-
June 23, 2022Robins Kaplan’s Antitrust Class Action Practice Recognized as Leader In The Field For Fourth Consecutive Year
-
July 14, 2022Summer Associate Webinar
-
July 18, 202240th Annual Public Justice Gala & Awards Presentation
-
July 21, 2022MAIBA Scholarship Golf Tournament
-
June 21, 2022Briefly: How To Oppose An Extension If You Really Need To
-
June 7, 2022Damned if You Do,
Damned if You Don’t -
June 7, 2022Take-Home COVID: The New Frontier?
-
July 1, 2022Markets Close Out Worst First-Half Performance in 50 Years
-
June 30, 2022Spirit Again Delays Shareholder Vote on Frontier Deal After JetBlue Sweetens Bid
-
June 29, 2022Despite Headwinds, Disney Reappoints Chapek as CEO Through 2025
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Consumer Alert: Abbott Laboratories Withdraws Its Obesity Drug Meridia
According to FDA, clinical trial testing of Meridia showed an increased risk of heart attacks and strokes in patients taking Meridia.
October 10, 2010
The drug maker Abbott Laboratories has agreed to take its weight loss and obesity drug Meridia (substance name sibutramine) off the market, the U.S. Food and Drug Administration ("FDA") announced Friday, October 8. According to FDA, clinical trial testing of Meridia showed an increased risk of heart attacks and strokes in patients taking Meridia.[1]
The new data showing that Meridia users suffer more heart attacks and strokes comes from the Sibutramine Cardiovascular Outcomes trial, known by its initials as the SCOUT trial. The SCOUT data demonstrated a 16% increase in risk of major adverse cardiovascular events (defined as non-fatal heart attack, non-fatal stroke, resuscitation after cardiac arrest and cardiovascular death) in patients treated with Meridia compared to patients taking a placebo.[2] At the end of the SCOUT trial, patients taking Meridia lost slightly more weight than patients taking placebo, but FDA has concluded that the risk for an adverse cardiovascular event from Meridia outweighed any benefit from that modest weight loss.[3]
In it's press release concerning the withdrawal, Abbott Laboratories instructs those taking Meridia to stop taking the drug and see their doctor for alternatives.[4]
Robins, Kaplan, Miller & Ciresi L.L.P. is investigating potential claims on behalf of Meridia patients. If you wish to speak to us about a potential claim or an injury caused by Meridia, please call Kathy Neuman, R.N., B.S.N. at 1-800-553-9910 or contact her via email at contact us.
[2] FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine) [10-8-2010]
[3] Id.
[4] Abbott Press Release, "Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S. (October 8, 2010).
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Gary L. Wilson
Partner
Related Publications
Damned if You Don’t
In Times of Crisis:
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.